Rebounds in Core Lab Services Offset Declines in COVID-19 Test Revenues
Second quarter diagnostics earnings were down, but not as much as predicted.
Second quarter diagnostics earnings were down, but not as much as predicted.
Users should realize that the FDA can extend the shelf life of a test when and if it receives additional data supporting such an extension.
While not nearly as robust as a year ago, diagnostic companies’ revenues held up surprisingly well in Q2 2022.
The agency is advising people to perform repeat, or serial testing after a negative result, regardless of symptoms.
Two recent studies show that most people see telehealth as a supplement to in-person visits, rather than a replacement.